Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | CCR9 | P51686 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24943617 | 0.80 | ALDH1A1 (0.36) | KCNH2CCR9ALDH1A1HPGDALOX15 | |
| SCHEMBL24943301 | 0.78 | KCNH2 (0.39) | KCNH2CCR9ALDH1A1HPGDALOX15 | |
| SCHEMBL21341730 | 0.76 | KCNH2 (0.35) | KCNH2CCR9ALDH1A1HPGDALOX15 | |
| SCHEMBL21341337 | 0.76 | KCNH2 (0.33) | KCNH2CCR9ALDH1A1HPGDALOX15 | |
| SCHEMBL24943790 | 0.74 | CCR9 (0.39) | KCNH2CCR9ALDH1A1HPGDHSD17B10 | |
| SCHEMBL24943615 | 0.73 | CCR9 (0.38) | KCNH2CCR9 | |
| SCHEMBL21341338 | 0.73 | CCR9 (0.40) | CCR9ALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL24630686 | 0.72 | KCNH2 (0.31) | KCNH2 | |
| SCHEMBL24944393 | 0.72 | OPRM1 (0.35) | KCNH2ALDH1A1HPGD | |
| SCHEMBL24943810 | 0.72 | CCR9 (0.37) | CCR9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230030115-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2023-02-02 | — | — | US | disclosed |
| US-20190276440-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230030115-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | ROCK1, ROCK2, RHOA | KCNH2 4406/4885CCR9 3518/4885ALDH1A1 4501/4885 |
| US-20190276440-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | ROCK1, ROCK2, RHOA | KCNH2 4406/4885CCR9 3518/4885ALDH1A1 4501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.